“In the third quarter, we were pleased to announce a positive outcome from the SPR994 Phase 3 interim pharmacokinetic analysis where an independent data review committee determined that SPR994 plasma PK levels in patients were comparable to levels seen in the Phase 1 trial of healthy volunteers. As plasma exposure is a strong determinant of clinical efficacy, these data support the dose selected for the Phase 3 trial and give us additional confidence in SPR994’s activity in complicated urinary tract infections, a therapeutic area where a significant unmet need exists for effective oral agents that have the potency to fight resistant pathogens,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “We are in a strong financial position with approximately
Recent Clinical Highlights and Upcoming Milestones
Spero’s lead product candidate, SPR994, has the potential to be the first oral carbapenem antibiotic approved for use in adults to treat MDR Gram-negative infections. A pivotal Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections (cUTI) entitled ADAPT-PO continues to enroll patients. This Phase 3 clinical trial compares an all oral regimen of SPR994 with an existing standard of care intravenous (IV) antibiotic, ertapenem, in approximately 1,200 patients with cUTI or acute pyelonephritis, randomized 1:1 in each arm. In
SPR720 is an orally administered antimicrobial agent being developed for the treatment of a rare, orphan disease, non-tuberculous mycobacterial (NTM) infections and other infections, including Mycobacterium tuberculosis. SPR720 is currently being evaluated in a double-blind, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of SPR720 in healthy volunteers. Spero expects to report top-line data from the Phase 1 clinical trial by year-end 2019. In
SPR206 is an IV-administered product candidate from Spero’s Potentiator Platform being developed as an innovative option to treat MDR Gram-negative bacterial infections. In July 2019, the U.S. Department of Defense awarded $5.9 million to further clinical development of SPR206 against drug-resistant infections. SPR206 is currently being evaluated in a first-in-human Phase 1 clinical trial, designed as a double-blind, placebo-controlled, single and multiple ascending dose, multi-cohort study in healthy subjects. Spero expects to report top-line data from the Phase 1 clinical trial by year-end 2019.
Third Quarter 2019 Financial Results
Spero reported a net loss for the third quarter ended September 30, 2019 of $17.7 million or $0.95 per common share, greater than the net loss reported for the same period in 2018 of $10.5 million or $0.60 per common share.
Total revenue for the third quarter of 2019 totaled $4.6 million, higher than third quarter 2018 revenues of $658,000. The year-over-year increase was due to greater funding for SPR994 received under our BARDA contract awarded in July 2018 that allows for reimbursement of up to $46.7 million for qualified expenses for SPR994 development,
Research and development expenses for the third quarter of 2019 of $18.5 million were higher than $8.5 million for the same period of 2018 due to greater spend on the SPR994 clinical program, partially offset by lower spend on the Potentiator Platform product candidates. General and administrative expenses for the third quarter of 2019 of $4.1 million were higher than $3.1 million for the same period of 2018, primarily due to increased headcount and facility-related costs.
Spero continues to expect that its research and development expenses will increase through year-end 2019 due to greater planned clinical spend associated with the SPR994 pivotal ADAPT-PO trial as enrollment scales, as well as the ongoing SPR720 and SPR206 Phase 1 clinical trials, along with increased personnel to support the clinical programs. Spero continues to expect general and administrative expenses to increase through year-end 2019 due to additional headcount and professional fees required to support SPR994 as it advances through a Phase 3 clinical trial and prepares for possible regulatory approval and commercialization.
As of September 30, 2019, Spero had cash and cash equivalents of $93.9 million, compared to $103.4 million as of June 30, 2019. In
Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan disease caused by pulmonary non-tuberculous mycobacterial (NTM) infections.
Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero’s lead product candidates generated from its Potentiator Platform are two IV-administered agents, SPR206 and SPR741, designed to treat MDR Gram-negative infections in the hospital setting.
Forward Looking Statements
This press release may contain forward-looking statements. These statements include, but are not limited to, statements about Spero’s expectation that positive results from a single pivotal Phase 3 clinical trial of SPR994 and ancillary supportive studies to be conducted in parallel with the Phase 3 trial will support the approval of SPR994; the initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs; statements regarding management’s assessment of the results of such preclinical studies and clinical trials; the timing of clinical data, including the availability of pharmacokinetic data from the lead-in cohort in the Phase 3 clinical trial of SPR994 and top-line data from the Phase 1 clinical trial of SPR720 and the Phase 1 clinical trial of SPR206; and Spero’s cash forecast and anticipated expenses, the sufficiency of its cash resources and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the FDA will accept a single pivotal study for approval of SPR994; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spero’s product candidates will advance through the preclinical development and clinical trial process on a timely basis, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.
Spero Investor and Media Contact:
Senior Director, Investor Relations
|Spero Therapeutics, Inc.|
|Condensed Consolidated Statements of Operations|
|(Unaudited, amounts in thousands, except share and per share data)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development||18,495||8,459||40,047||24,758|
|General and administrative||4,133||3,134||11,803||9,238|
|Total operating expenses||22,628||11,593||51,850||33,996|
|Loss from operations||(17,985||)||(10,935||)||(37,333||)||(31,722||)|
|Other income (expense)||268||472||1,394||659|
|Net loss attributable to common shareholders of Spero Therapeutics, Inc.||$||(17,717||)||$||(10,463||)||$||(35,939||)||$||(31,063||)|
|Net loss per share attributable to common shareholders per share, basic and diluted||$||(0.95||)||$||(0.60||)||$||(2.01||)||$||(2.01||)|
|Weighted average shares outstanding, basic and diluted:||18,659,079||17,471,462||17,859,829||15,417,087|
|Spero Therapeutics, Inc.|
|Condensed Consolidated Balance Sheet Data|
|(Unaudited, amounts in thousands)|
|September 30,||December 31,|
|Cash, cash equivalents and marketable securities||$||93,856||$||115,443|
|Total stockholder's equity||93,034||115,855|
|Total liabilities and stockholders' equity||$||112,510||$||129,006|
Source: Spero Therapeutics, Inc.